Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates

Article in Nature Medicine reports data from study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that Arevirumab-3, its lead immunotherapeutic […]

Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates Read More »